Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A sin

Date publication

avril 2024

Journal

Journal of the American Academy of Dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38043594

Résumé

Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial.

Mots clés

chemotherapy, clinical research, cutaneous melanoma, drug response, histopathologic regression, immune checkpoint inhibition, oncology, targeted therapy

Référence

J Am Acad Dermatol. 2024 04;90(4):739-748